Exchange: NASDAQ·Updated 11:12 AM EDT
News
all
press releases
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference
Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.
Stocktwits
More News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Smart Beta ETF report for IBB
Zacks
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.
Stocktwits
LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset
Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.
Stocktwits
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer
During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.
Stocktwits
OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’
After two rejections, retail investors are hopeful the FDA will approve Outlook Therapeutics’ Lytenava for the treatment of wet AMD.
Stocktwits
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.
Stocktwits
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing
Multiple analysts reiterated optimism on CMPS stock after the company announced 26-week data from its second late-stage trial of COMP360 in treatment-resistant depression.
Stocktwits
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism
Agios said the U.S. Food and Drug Administration granted Priority Review to its supplemental new drug application for Mitapivat in sickle cell disease.
Stocktwits
ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns
Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study.
Stocktwits

Advertisement|Remove ads.